News
RDY
12.47
+2.17%
0.27
Dr. Reddy’s Receives Two-Observation USFDA Form 483 After PAI at FTO-11
TipRanks · 1d ago
Dr Reddy's Says FDA Completed Pre-Approval Inspection At The FTO-11 Manufacturing Facility In Pydibhimavaram
Benzinga · 1d ago
Dr. Reddy’s Sets October 23 Date for Q2 FY27 Results and Global Earnings Call
TipRanks · 2d ago
Dr. Reddy’s U.S. Subsidiary Hit with Modest IRS Penalty, Assessed as Non‑Material
TipRanks · 4d ago
Weekly Report: what happened at RDY last week (0928-1002)?
Weekly Report · 4d ago
Analysts Offer Insights on Healthcare Companies: Zentek (OtherZTEKF) and Dr Reddy’s Laboratories (RDY)
TipRanks · 10/01 15:10
Dr Reddy's Labs Price Target Raised to $1450.00/Share From $1040.00 by Citigroup
Dow Jones · 09/29 17:58
Dr Reddy's Labs Raised to Buy From Sell by Citigroup
Dow Jones · 09/29 17:58
Citigroup Upgrades Dr Reddy's Laboratories to Buy, Raises Price Target to $1450
Benzinga · 09/29 17:51
Dr. Reddy's North America Revenue Expected to Trough -- Market Talk
Dow Jones · 09/29 04:02
Dr. Reddy’s double-upgraded to Buy from Sell at Citi
TipRanks · 09/29 01:35
Weekly Report: what happened at RDY last week (0921-0925)?
Weekly Report · 09/28 10:03
Dr. Reddy’s Schedules October 23 Board Meet, Closes Trading Window Ahead of Q2 Results
TipRanks · 09/22 18:51
Dr. Reddy’s Schedules Nomura-Led Investor Meet in Hyderabad
TipRanks · 09/21 17:57
Weekly Report: what happened at RDY last week (0914-0918)?
Weekly Report · 09/21 10:04
Dr. Reddy’s, Takeda Seal Exclusive Deal to Launch First Approved Dengue Vaccine in India’s Private Market
TipRanks · 09/18 10:48
Dr Reddy's Laboratories Q1 2027 Earnings Call Transcript
Benzinga · 09/17 07:42
Dr. Reddy’s Reports FDA Records Assessment at Mexican API Plant Concluding with Two Observations
TipRanks · 09/14 10:58
Weekly Report: what happened at RDY last week (0907-0911)?
Weekly Report · 09/14 10:08
Immutep provides update on development strategy for eftilagimod alfa
TipRanks · 09/11 12:15
More
Webull provides a variety of real-time RDY stock news. You can receive the latest news about Dr Reddys Labs through multiple platforms. This information may help you make smarter investment decisions.
About RDY
Dr. Reddy’s Laboratories Limited is an India-based pharmaceutical company. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. It works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates.